e-ISSN: 2394-2967
logo

British Journal of Medical and Health Research

📢 Latest Update: Call for Papers: Special Issue on Medical and Health Research – Submit to British Journal (BJMHR) by March 31, 2026

📢 Latest Update: Call for Papers: Special Issue on Medical and Health Research – Submit to British Journal (BJMHR) by March 31, 2026

Volume 9, Issue 2 - 2022 (February 2022 Issue 2)

Volume 9 Issue 2 Cover

Issue Details:

Volume 9 Issue 2
Published:Invalid Date

Editorial: February 2022 Issue 2

Welcome to the 2022 issue of British Journal of Medical and Health Research. This issue showcases the remarkable breadth and depth of contemporary research across multiple disciplines. From cutting-edge applications of machine learning in climate science to the revolutionary potential of quantum computing in drug discovery, our featured articles demonstrate the power of interdisciplinary collaboration in addressing global challenges.

We are particularly excited to present research that bridges traditional academic boundaries, reflecting our journal's commitment to fostering innovation through cross-disciplinary dialogue. The integration of artificial intelligence with environmental science, the application of blockchain technology to supply chain management, and the convergence of urban planning with smart city technologies exemplify the transformative potential of collaborative research.

As we continue to navigate an era of rapid technological advancement and global challenges, the research presented in this issue offers both insights and solutions that will shape our future. We thank our authors, reviewers, and editorial board members for their continued dedication to advancing knowledge and promoting scientific excellence.

Dr Hemangi J Patel
Editor-in-Chief
British Journal of Medical and Health Research

Articles in This Issue

Showing 1 of 1 articles
Research PaperID: BJMHR0902001

Angiotensin-Converting Enzyme 2 (ACE2) gene Polymorphism and susceptibility to Covid-19 infection

Mohammed Hussein

ABSTRACT (COVID-19), SARS-CoV-2 originated from Wuhan, China and has led to a worldwide pandemic. COVID-19 is a novel emerging infectious disease caused by SARS-CoV-2 characterized as atypical pneumonia. Most of the cases were epidemiologically linked to the seafood and animal market. Novel Coronavirus strains are spread from person to person through contaminated droplets from a person who is sick with the illness (through coughing or sneezing) or contaminated hands. The virus can spread through touching an infected surface. The incubation period extends from 1 to 14 days (that means the amount of time from being exposed to the virus to showing symptoms). The symptoms are: Sore throat, Fever, Shortness of breath, Cough, Headache. Most of the patients with COVID-19 have mild or moderate disease, however up to 5-10% present with severe and even life-threatening disease course. The entry of SARS-CoV-2, the agent that causes COVID-19, into the cell occurs by binding viral spike proteins to angiotensin-converting enzyme 2 (ACE2) receptors of the host membrane. It was suggested that increased susceptibility to COVID-19 infection is associated with the expression of the target ACE2 receptor in the epithelium exposed to the virus the aim of this article is to summarize the latest literature and explore how ACE2 variants influence an individual’s susceptibility to SARS-CoV-2 infection.

COVID-19. Angiotensin-converting enzyme 2 (ACE2).
50,166 views
15,175 downloads

Contributors:

 Mohammed Hussein